We earn commissions from brands listed on this site, which influences how listings are presented. Advertising Disclosure
Last offers update: March 23
How This Treatment Works
Wegovy® is a prescription treatment containing semaglutide, a GLP-1 receptor agonist. It supports weight management by working with hormone signals involved in appetite and digestion. Many people notice they feel satisfied with smaller portions, think about food less often, and find it easier to follow a reduced-calorie routine consistently over time.
Wegovy is indicated for chronic weight management together with a reduced-calorie diet and increased physical activity. The U.S. label includes adults with obesity, adults with overweight plus at least one weight-related condition, and pediatric patients ages 12+ with obesity.
Wegovy also has an FDA-approved cardiovascular indication: it can be used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight, alongside diet and activity.
In a major clinical trial (STEP 1), adults taking once-weekly semaglutide 2.4 mg had an average weight change of –14.9% at 68 weeks, compared with –2.4% with placebo (results vary by person).
Wegovy treatment usually means a program that includes a medical evaluation, a prescription when appropriate, and ongoing support while you use brand-name Wegovy as directed.
Wegovy is best known as a once-weekly injection, and the label describes weekly dosing on the same day each week. In updated U.S. labeling, Wegovy also appears as a tablet formulation with specific directions for how it’s taken (daily, on an empty stomach, with a small amount of water). Which form is available to you depends on what’s offered in your region and what your prescriber determines is appropriate.
One important rule from the FDA: Wegovy should not be used in combination with other semaglutide-containing products or other GLP-1 receptor agonists.
What to Anticipate
Wegovy is designed to be a gradual, step-by-step process. Many people notice appetite changes earlier, while weight change typically builds over weeks and months. Clinical trials measured outcomes over long periods (like 68 weeks), which matches how these treatments are intended to support sustained progress rather than quick fixes.
Most people start at a lower dose and increase over time, which is done to improve tolerability, especially for stomach-related side effects. Your prescriber typically monitors how you’re doing and adjusts the plan based on your response and comfort.
The most common side effects reported with Wegovy are gastrointestinal, such as nausea, diarrhea, vomiting, constipation, and stomach pain, with other common effects like headache and fatigue also reported. Many people find these are most noticeable when starting or when doses increase, then improve as the body adapts.
If side effects feel persistent or concerning, reaching out to the prescribing clinician is important. Dose timing, escalation pace, and supportive strategies can sometimes make the experience more manageable without sacrificing safety.
Since Wegovy itself is the same medication, what typically differs between options on this page is the overall experience: how clear the monthly pricing is, what follow-ups are included, how refills work, and how easy it is to contact a clinician if you have questions.
A good fit is usually the option that makes it easiest for you to stay consistent, understand what you’re paying for, and get help quickly if something doesn’t feel right.
Costs and Coverage
Wegovy costs can vary a lot depending on insurance coverage and program structure. Some people may need prior authorization or meet specific plan criteria, and some may pay out of pocket. Because the “real” monthly total can include more than the medication itself, it helps to compare what you would actually pay each month and what’s included in that amount.
If cardiovascular risk reduction is part of your medical situation, that indication may also affect how coverage is handled for some people, depending on the insurer and plan rules.
Lifestyle Integration
Wegovy is indicated to be used alongside a reduced-calorie diet and increased physical activity. Many people find the medication makes those changes more achievable by reducing appetite pressure, but the routines you build are what support long-term maintenance.
Wegovy has a boxed warning because semaglutide caused thyroid C-cell tumors in rodents, and it is contraindicated if you have a personal or family history of medullary thyroid carcinoma (MTC) or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Pregnancy is another key consideration. For weight reduction or cardiovascular risk reduction, the label advises discontinuing Wegovy when pregnancy is recognized, and discontinuing at least 2 months before a planned pregnancy due to semaglutide’s long half-life.
The FDA also highlights warnings related to pancreatitis, gallbladder problems, low blood sugar (especially when used with certain diabetes medicines), kidney injury, diabetic retinopathy, increased heart rate, and suicidal behavior or thinking. These risks are why a real medical evaluation and ongoing monitoring matter.
This content is educational and does not replace medical advice. Wegovy is a prescription medication and should be used only under the care of a licensed clinician. Individual results and side effects vary.
Wegovy contains semaglutide, a GLP-1 receptor agonist that influences appetite and digestion signals, helping many people feel full sooner and reduce calorie intake more consistently.
Wegovy is indicated (with diet and activity) to reduce excess body weight and maintain weight reduction long term in adults with obesity, adults with overweight plus at least one weight-related condition, and pediatric patients ages 12+ with obesity.
Yes. The FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, alongside diet and activity.
Wegovy is commonly used as a once-weekly injection. The label also describes a tablet formulation taken once daily with specific instructions; availability depends on what’s offered where you live and what your prescriber selects.
Many people notice appetite or fullness changes earlier, while weight change typically builds over weeks and months. In STEP 1, average weight change at 68 weeks was –14.9% with semaglutide 2.4 mg versus –2.4% with placebo (individual results vary).
Common side effects include nausea, diarrhea, vomiting, constipation, stomach pain, headache, and fatigue, among others listed in FDA materials.
Yes. Wegovy has a boxed warning about thyroid C-cell tumors observed in rodents and should not be used with a personal/family history of MTC or with MEN 2. It also carries additional warnings (such as pancreatitis and gallbladder problems).
The FDA notes Wegovy should not be used in combination with other semaglutide-containing products or other GLP-1 receptor agonists.
For Wegovy injection, the label provides timing guidance based on how close your next scheduled dose is (48 hours), and notes that if you miss doses for 2 or more weeks you should talk with your prescriber about how to restart.
Focus on your total monthly cost and what’s included (medical evaluation, follow-ups, refill process, shipping, and support access), because those factors often determine how smooth and sustainable the experience will be.
